Chun-Geon Park

Simultaneous determination of luteolin and luteoloside in dandelions using HPLC

The content of the two flavonoids, luteolin and luteoloside, in dandelions was determined by high-performance liquid chromatography. A Nucleosil®100-5C18 column was used for the determination of luteolin and luteoloside concentrations. The mobile phase was a mixture of acetonitrile and water containing 0.1% formic acid (99.9:0.1, v/v). The gradient elution program was 10% to 23% acetonitrile within 60 min at a flow rate of 1.0 mL·min−1. The ultraviolet spectra were recorded at 350 nm for the identification of the two flavonoids. The contents of luteolin and luteoloside were highest in T. officinale flowers (5.817 ± 0.030 mg·g−1) and in T. coreanum leaves (6.205 ± 0.087 mg·g−1), respectively. The total content of luteolin and luteoloside in T. coreanum was about 1.3–2 times higher than that found in T. ohwianum and T. officinale.

Cultivation and Characteristics of Licorice F 1 (Glycyrrhiza glabra x G. uralensis) Lines

Licorice, a traditional Korean medicinal plant, is recognized for its main active ingredient, glycyrrhizin. The level of glycyrrhizin in Chinese licorice (Glycyrrhiza uralensis ) is lower than the reference level (2.5%) set by the Korean Pharmacopoeia, reducing its value as a medicinal herb. In this study, we aimed to overcome this problem by generating an interspecific licorice hybrid by crossing European licorice (G. glabra ) with Chinese licorice, resulting in the production of 32 F1 lines. A comparison of genetic traits revealed variations in glycyrrhizin content among lines, ranging from 1.5 to 5.6%, with a mean value of 3.2%; these values are higher than that of the parental plants. Additionally, 25 lines (78.1%) had a glycyrrhizin content greater than 2.5%, which is higher than the reference level set by the Korean Pharmacopoeia. Four of these lines had glycyrrhizin levels higher than the WHO recommended level of 4.0%. A comparison of phenotypic characteristics showed that the leaves of the hybrids possessed all of the characteristics of European and Chinese licorice; however, the stems of most hybrids had characteristics of European licorice. Finally, we determined the genetic distances of 34 samples of Glycyrrhiza plants (parents, 32 F₁ lines) by random amplified polymorphic DNA (RAPD); the F₁ lines showed a close genetic distance. We plan to develop to a cultivar using five of these lines (glycyrrhizin content < 4.0%).

A disease resistance and high yielding Rehmannia glutinosa Libosch. ex Steud. cultivar ‘Tokang’

A new Rehmannia glutinosa cultivar ‘Tokang’ was derived from ‘Jihwang 1’ seedlings by medicinal crop breeding team of National Institute of Horticulture and Herbal Science, RDA in 2009. It has pink flower, dark brown seed coat, light yellow root cortex. The plant type was some rising from the ground. The content of catalpol and extract were higher than the ‘Jihwang 1’(check variety). The content of catalpol was 4.55% and the extract was 71.2%. It showed stronger resistance to root rot compare with the ‘Jihwang 1’. The regional yield trials were conducted at three different locations from 2007 to 2009. The average yield of ‘Tokang’ was 21.1ton/ha, which was 12% more than the ‘Jihwang 1’. This cultivar is adaptable to the whole of Korea except for mountain areas. (Registration No. 4725)

Isolation and identification of phytochemicals and biological activities of Hericium ernaceus and their contents in Hericium strains using HPLC/UV analysis.

ETHNOPHARMACOLOGICAL RELEVANCE Hericium ernaceus has been traditionally used for the treatment of dyspepsia, gastric ulcer and enervation in traditional Chinese medicine for a long time. AIM OF THE STUDY To examine the effect of Hericium strains on their ability to inhibit LPS and interferon-γ induced NO production in cell culture and the bioassay correlation of hericenone C, D, F, isolated from H. ernaceus. MATERIALS AND METHODS Hericenone C, D, F were isolated from H. ernaceus by open column chromatography and identified on the basis of spectroscopic analyses including (1)H NMR, (13)C NMR and MS. The amounts of hericenone C, D, and F in Hericium strains were determined by HPLC/UV analysis. In order to investigate the anti-inflammatory effect of Hericium strains extracts, RAW 264.7 cells were treated with 200μg/mL of Hericium strains extracts for 48h. Cell growth was assessed by MTT assay. RESULTS Phytochemical constituents were isolated from H. ernaceus by open column chromatography. Their structures were elucidated as hericenones C, D, and F on the basis of spectroscopic analyses including (1)H NMR, (13)C NMR and MS. The amounts of hericenones C, D, and F in Hericium strains were determined by HPLC/UV analysis. Hericenones C, D, and F contents were highest in Norugungdenglee-2 (8.289±0.593mg/g), KFRI-1453 (4.657±0.462mg/g), and KFRI-1093 (5.408±0.420mg/g) strains, respectively. All Hericium strains extracts tested inhibited the lipopolysaccharide- and interferon-γ-induced inflammatory activity of RAW264.7 cells. The strain KFRI-1093 about 39.6% reduced NO generation with compared to control. CONCLUSION We believe that the anti-inflammatory effect of KFRI-1093 was due to hericenone F content. Our results contribute towards validation of the traditional use, natural drugs and health supplements. And also, the developed simple, accurate and rapid LC method can be used determinate the content of hericenones from other Hericium strains.

693 The gp130/STAT3 Axis Is Modulated by Lipotoxic Stress and Activated in Humans With Nonalcoholic Fatty Liver Disease

A S L D A b st ra ct s random-effects model; Q-statistic with p-value 50% for both estimates). SVR rates in HCV-6 patients were 79.1% (CI=73.2-84.0%) if treated for 48 weeks and 58.7% (CI=46.0-70.2%) if treated for 24 weeks. When compared to HCV-1 patients, those with HCV-6 treated for 48 weeks had higher SVR, OR 2.73 (1.69-4.41, p<0.001) (Figure 1). This difference was not statistically significant when comparing HCV-6 patients treated for only 24 weeks to HCV-1 patients, OR 1.80 (0.72-4.48, p=0.206). SVR in patients with early virologic response (EVR, undetectable HBV RNA PCR at week 12 of therapy) was 66% (CI=54.2-76.4%) for HCV-1 and 81.6% (CI=75.3-86.6%) for HCV-6 patients treated for 48 weeks. There was no statistically significant difference in SVR between HCV-6 patients treated for 48 weeks versus patients with HCV-1 if they all had EVR, OR 2.02 (CI=0.864.76, p=0.106). Conclusions: Patients with HCV-6 treated for 48 weeks had higher SVR than patients with HCV-1 (79.1% vs. 71.8%, OR=2.73, p<0.001); however, SVR for Asian HCV-1 appeared much higher than SVR to PEG IFN+RBV for HCV-1 in pivotal registration trials with mostly Western patients. In patients with EVR, there is no difference in SVR rates between HCV-1 and HCV-6 who were treated for 48 weeks.